short at 11.49

On Nov 24, 8:57 am, JPSDvp27 <jpsdv...@gmail.com> wrote:

Not a chance

On Nov 24, 9:10 am, Johnny <hyams.j...@gmail.com> wrote:

Turn Your $1,000 Into Over 2 Million Dollars With Their Help  at
http://www.stocksmastermind.com

Opinions?

I did for last almost 2 years when i got  this for $6.70. still
holding

On Nov 24, 12:02 am, Phil Chen <philchen....@gmail.com> wrote:

this stock skyrocketed and never looked back.  If there were any
shorters, they are hurting bad. Who longed this bad boy?

http://n4sd4q.blogspot.com/2009/11/origin-agritech-ltd-nasdaqseed.html

About Health Discovery Corporation

Health Discovery Corporation (HDC) is a pattern recognition company
that uses mathematical techniques to analyze large amounts of data to
uncover patterns that might otherwise be undetectable. The Company
operates primarily in the emerging field of molecular diagnostics
where such tools are critical to scientific discovery. The Company’s
principal asset is its intellectual property, which includes
mathematical algorithms called Support Vector Machines (SVM) and
Fractal Genomic Modeling (FGM), as well as biomarkers that the Company
discovered by applying its SVM and FGM techniques to complex genetic
and proteomic data. HDC also endeavors to develop its own product line
of newly discovered biomarkers and pathways that include human genes
and genetic variations, as well as gene, and metabolite expression
differences. The principal healthcare market for its pattern
recognition technology and biomarker discoveries is medical
diagnostics, particularly the field of molecular diagnostics.

Company Web site:
http://www.healthdiscoverycorp.com/

* HDC recently entered into royalty-bearing licenses for its new urine-
based prostate cancer test with Quest
Diagnostics Incorporated and Abbott Laboratories for development and
commercialization

* Major Partnerships with Pfizer (NYSE), Abbott (NYSE), Quest
Diagnostics (NYSE), CLRT (NASD), IART (NASD), BRKR(NASD)

* HDC has also partnered with Pfizer Inc. for use of HDC’s SVM and SVM-
RFE pattern recognition technology in Pfizer’s global research and
development. HDC has also entered into a license with Smart
Personalized Medicine, LLC (“SPM”), a privately-held company, founded
by Dr. Richard Caruso, Chairman and founder of Integra Life Sciences
(NasdaqGS: IART - News) to develop a superior breast cancer prognostic
test using HDC’s SVM technology in cooperation with MD Anderson Cancer
Center. HDC has a fifteen percent equity position in SPM and HDC will
receive royalties from this new breast cancer prognostic test.

* HDC has entered into a development and license agreement with DCL
Medical Laboratories, LLC, for the
collaborative development and commercialization of SVM-based computer
assisted diagnostic tests for the independent detection of ovarian,
cervical and endometrial cancers.

credits to $heff from investorhub

* They have a replacement for the current PSA test and for prostate
biospies as well! PSA test is what the
current medical community uses to gauge whether you may need a
prostate biopsy to check for cancer. HDVY's test replaces both PSA
tests and prostate biopsies

* Current tests have a 25% false positive result for cancer. That
means that 1/4 of all men are misdiagnosed
with prostate cancer and they don't have cancer at all!

* HDVY's test is 94 to 96% accurate and superior to current testing
methods.

* Clarient a small cancer diagnostic lab is already selling this test
w/ there 60 sales people. It is great that
Quest and Abbot are on board. Put the big dogs out there against each
other and let the bidding war begin. This thing reeks of a buyout once
the new prostate test's plural take hold and gain traction.

credits to hellnomofuggerfrom yahoo forum

Health Discovery Corporation’s Dr. Stephen Barnhill Tells Participants
at London Conference That Biomarkers
Patented by His Company Promise to Revolutionize The Field of
Molecular Diagnostics
http://www.businesswire.com/portal/site/google/ndmViewId=news_view&ne...

Quest services 50% of the physicians & hospitals in the U S.
http://www.wsw.com/webcast/lz6/dgx/

Former Deputy FDA Commissioner John Norris Appointed Chief Operating
Officer at Health Discovery Corporation
http://www.businesswire.com/portal/site/google/?ndmViewId=news_view&n...

Health Discovery Corporation Announces Additional Issued Patents and
Notices of Allowance to Its Intellectual
Property Portfolio
http://www.marketwatch.com/story/health-discovery-corporation-announc...

Barchart rated "BUY":
http://quote.barchart.com/texpert.asp?sym=hdvy&code=BSTK

Great products:
http://www.healthdiscoverycorp.com/prostatecancer.php

Company fillings are good--$2,100,000 cash on hand:
http://www.pinksheets.com/pink/quote/quote.jsp?symbol=hdvy

--------------

"At this point in time when the PSA has been shown to be ineffective
in identifying clinically significant
prostate cancer, Health Discovery Corporation's recent biomarker
discovery creating a genomic based test that separates grade 4/5
prostate cancer, the most malignant and clinically significant type of
prostate cancer from BPH (benign prostatic hypertrophy) and normal
prostate with a very high degree of accuracy is an exciting and
outstanding accomplishment"

Dr. Thomas A. Stamey
Professor & Founding Chairman
Department of Urology
Stanford University Medical Center

--------------

Health Discovery Corporation new gene-based molecular diagnostic test
for prostate cancer has now successfully completed it’s Phase III
double-blind clinical trial and is now ready for commercialization to
be used by physicians on their patients at risk of having prostate
cancer. The new prostate cancer test will be performed at Clarient’s
Clinical Laboratory in Aliso Viejo, CA. HDC will receive 30% royalty
on each test performed.Results from Phase I, Phase II and Phase III
double-blinded clinical validation studies now completed with prostate
tissues obtained from multiple sites, including those tested in
collaboration with MD Anderson Cancer Center, demonstrated a very high
success rate for identifying the presence of Grade 3 or higher
prostate cancer cells (clinically significant cancer), as well as,
normal and BPH (benign prostatic hyperplasia) cells. To date, 322
prostate tissues have been tested. The combined results of the
recently completed double-blinded clinical validation studies
demonstrated that the new gene-based molecular diagnostic test for
prostate cancer achieved a Sensitivity of 90% for correctly
identifying the presence of Grade 3 or higher prostate cancer cells,
and a Specificity of 97% for correctly identifying non-cancer cells
(normal and BPH), representing an overall test accuracy of 93%.

"The excellent results seen in Phase I, Phase II, and Phase III double-
blinded clinical trials validate the
scientific accuracy and robustness of the HDC gene-based molecular
diagnostic test for prostate cancer.
Physicians that are diagnosing and treating prostate cancer patients
will be greatly assisted by the additional
information that this new prostate cancer test will add to their
decision making process."

Dr. Herbert Fritsche
Professor and Chief of Clinical Chemistry
M.D. Anderson Cancer Center

---------------

This is a great long term investment, always do your own due diligence
before you jump into it, peace out!!!

http://tjts.blogspot.com/2009/11/if-chart-said-breaking-soon-it-will....

Chembio Diagnostics: A buyer's delight
http://seekingalpha.com/instablog/492120-jospeh-krueger/33426-chembio...

Stated timeline for expected approvals for DPP tests:
Market DPP® HIV 1/2 Screening Assay

Developing World: end 2009-start 2010
CE Mark: 1st Half 2011
US FDA: 1st Half 2011
DPP® Syphilis Screen & Confirm
Developing World:  end 2009-start 2010
CE Mark: 1st Half 2010
US FDA: 1st Half 2011

How DPP HIV Oral Fluids works:
http://www.chembio.com/video-DPP_HIV-OralFluids/DPP_HIV-OralFluids.html

Chembio Diagnostics to present possibilities of OTC home-use HIV test
kits at the FDA meeting:
http://www.news-medical.net/news/20091118/Chembio-Diagnostics-to-pres...

Chembio Diagnostics, Inc., along with its subsidiaries, develops,
manufactures and markets diagnostic tests that detect infectious
diseases. The Company’s main products commercially available are three
rapid tests for the detection of human immunodeficiency virus (HIV)
antibodies in whole blood, serum and plasma samples, two of which were
approved by the United States Food and Drug Administration (FDA)
during the year ended December 31, 2006. In addition, the Company has
a fourth rapid HIV test, developed on its Dual Path Platform (DPP)
technology, for the detection of antibodies to HIV in oral fluid
samples, as well as whole blood, serum and plasma samples. These
products employ single path lateral flow technology, which it has
licensed from Inverness Medical Innovations, Inc. (Inverness), which
is also its marketing partner for the FDA-approved products in the
United States under its Clearview brand.

Company Web site:
http://www.chembio.com/index.html

insider selling at $ 9.60 of 1.65 million shares

On Nov 23, 1:38 pm, gh <hardik4u5...@yahoo.com> wrote:

Target price end of this week.. 8.03

On Nov 23, 1:33 pm, gh <hardik4u5...@yahoo.com> wrote:

they got the approval. but seems like it woudnt make a bihg diffrence
in balance sheet.. market is appriciating alot.. sell it ( only my
opinion) book profit ..thts the smart choice.. dont regeret later on..
thnx for reading..

PennyStockCoach at www.pennystockcoach.com is so confident you will
make money on his plays he asks you to sign up to covestor to show the
world! Expect profits and enjoy them. He has his own little varsity
team (chatroom) http://pennystockcoach.com/varsity team.html
 Losing is not in the Varsity Team vocabulary. I recommend signing up
to the newsletter soon because the longer you wait the more $$$ you
are missing out on.

This stock just brokeout after next generation technology
announcement !!

this company revenue 49million $ per quarter !!

this new technology 800million -1 billion $ revenue !!

tomorrow open 4$ like NLST and next week 20$